Trials / Completed
CompletedNCT01884350
Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,217 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks
Detailed description
SPAF=Stroke Prevention in Atrial Fibrillation ISTH=International Society on Thrombosis and Hemostasis Primary Purpose: Other: To measure adherence to the study medication using an electronic monitoring device over the first 24 weeks on study medication
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban |
Timeline
- Start date
- 2013-10-15
- Primary completion
- 2016-01-20
- Completion
- 2016-01-20
- First posted
- 2013-06-24
- Last updated
- 2019-08-19
- Results posted
- 2019-08-19
Locations
220 sites across 7 countries: Belgium, France, Germany, Italy, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01884350. Inclusion in this directory is not an endorsement.